Heart failure with preserved ejection fraction: Fighting misconceptions for a new approach

Arquivos Brasileiros de Cardiologia

Volumn 96, Issue 6, 2011, Pages 504-513

  Fontes Carvalho, Ricardo ^a,b   Leite Moreira, Adelino ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Demographic aging; Heart failure therapy; Stroke volume; Ventricular function

Indexed keywords

ALDOSTERONE ANTAGONIST;

BLOOD FLOW VELOCITY; CHRONIC LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DIASTOLE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; EXERCISE TEST; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART VENTRICLE REMODELING; HEART VOLUME; HUMAN; HYPERTENSION; KIDNEY FAILURE; LUNG VEIN; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE; THERAPEUTIC MISCONCEPTION; TISSUE DOPPLER IMAGING; VEIN BLOOD FLOW;

HEART FAILURE; HUMANS; STROKE VOLUME; TRUTH DISCLOSURE;

EID: 79960978741     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2011000600012     Document Type: Review

References (64)

1. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.Eur Heart J. 2008; 29 (19): 2388-442.
2. Tribouilloy C, Resinaru D, Mahjoub H, Souliére V, Levy F, Peltier M, et al. Prognosis of heart failure with preserved ejection fraction:a 5 year prospective population-based study. Eur Heart J. 2008; 29 (3): 339-4.
3. Bhatia RS, Tu J, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006; 355 (3): 260-9.
4. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007; 50 (8): 768-77.
5. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part I. Diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002; 105 (11): 1387-93.
6. Owan TE, Hodge D, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006; 355 (3): 251-9.
7. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the ADHERE Database. J Am Coll Cardiol. 2006; 47 (1): 76-84.
8. Moutinho MA, Colucci FA, Alcoforado V, Tavares LR, Rachid MB, Rosa ML, et al. Heart failure with preserved ejection fraction and systolic dysfunction in the community. Arq Bras Cardiol. 2008; 90 (2): 132-7.
9. Brutsaert DL, De Keulenaer. Diastolic heart failure: a myth. Curr Opin Cardiol. 2006; 21 (3): 240-8.
10. De Keulenaer GW, Brutsaert D. The heart failure spectrum: time for a phenotype-oriented approach. Circulation. 2009; 119 (24): 3044-6.
11. Zille MR. Heart failure with preserved ejection fraction: is this DHF? J Am Coll Cardiol. 2003; 41 (9): 1519-22.
12. Lee DS, Gona P, Vasan RS, Larson MB, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the NHLB Institute. Circulation. 2009; 119 (24): 3070-7.
13. Chen HH, Lainchbury J, Senni M, Bailey KR, Redfield MM. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail. 2002; 8 (5): 279-87.
14. Zile MR, Baicu C, Bonnema DD, Diastolic heart failure: definitions and terminology. Prog Cardiovasc Dis. 2005; 47 (5): 307-13.
15. Leite-Moreira AF. Current perspectives in diastolic dysfunction and diastolic heart failure. Heart. 2006; 92 (5): 712-8.
16. Fontes-Carvalho R, Leite-Moreira AF. The pathophysiology of heart failure with preserved ejection fraction and its therapeutic implications. Rev Port Cardiol. 2009; 28 (1): 63-82.
17. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van Der Velden J, Stienen GJ, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006; 113 (16): 1966-73.
18. Borbély A, Falcao-Pires I, van Heerebeek L, Hamdani N, Edes I, Gavina C, et al. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res. 2009; 104 (6): 780-6.
19. Ahmed SH, Clark L, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.Circulation. 2006; 113 (17): 2089-96.
20. Spinale FG, Coker M., Heung LJ, Bond BR, Gunasinghe HR, Etoht, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000; 102 (16): 1944-9.
21. Periasamy M, Jansen P. Molecular basis of diastolic dysfunction. Heart Fail Clin. 2008; 4 (1): 13-21.
22. Hunt SA, Abraham W, Chin MH, Feldman AM, Francis S, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the ACC Foundation/AHA Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation.J Am Coll Cardiol, 2009; 53 (15): e1-e90.
23. Zile MR, Baicu C, Gaasch WH. Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004; 19 (19): 1953-9.
24. Paulus W, Tchoppe C, Sanderson J, Rusconi C, Flachskampf FE, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007; 28 (20): 2539-50.
25. Redfield MM, Jacobsen S, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289 (2): 194-202.
26. Kuznetsova T, Herbotz L, Lopez B, Jin Y, Richart T, Thys L, et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail. 2009; 2 (2): 105-12.
27. Maurer MS, King D, El-Khoury R, Packer M, Burkhoff D. Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail. 2005; 11 (3): 177-87.
28. Maeder M, Kaye D, Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol. 2009; 53 (11): 905-18.
29. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003; 107 (5): 714-20.
30. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin. 2008; 4 (1): 23-36.
31. Borlaug BA, Melenovski V, Russell SD, Kessler K, Pacak K, Becker LC, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006; 114 (20): 2138-47.
32. Maurer MS, Burkhoff D, Fried LP, Gottdiener J, King DL, Kitzman DW. Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol. 2007; 49 (9): 972-81.
33. Wang J, Khoury D, Yue Y, Torre-Amione G, Nagueh SF. Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. Eur Heart J. 2008; 29 (10): 1283-9.
34. Tan YT, Wenzelburger F, Lee E, Heatlie G, Leyva F, Patel K, et al. The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol. 2009; 54 (10): 36-46.
35. Westermann D, Kasner M, Steendijk P, Spillmann F, Riead A, Weitmann K, et al. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008; 117 (16): 2051-60.
36. Kitzman DW, Higginbotham M, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol. 1991; 17 (5): 1065-72.
37. Bruch C, Gradaus R, Gunia S, Breithardt G, Wichter T. Doppler tissue analysis of mitral annular velocities: evidence for systolic abnormalities in patients with diastolic heart failure. J Am Soc Echocardiogr. 2003; 16 (10): 1031-6.
38. Yip G, Wang M, Zhang Y, Fung JW, Ho PY, Sanderson JE. Left ventricular long axis function in diastolic heart failure is reduced in both diastole and systole: time for a redefinition? Heart Fail Clin. 2002; 87 (2): 121-5.
39. Nagueh SF, Appleton C, Gillebert TC, Marino PN, Oh JK, Smiseth AO, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009; 10 (2): 165-93.
40. Mesquita E, Jorge A. Heart failure with normal ejection fraction: new diagnostic criteria and pathophysiological advances. Arq Bras Cardiol. 2009; 93 (2): 180-7.
41. Somaratne JB, Whalley G, Gamble GD, Doughty R. Restrictive filling pattern is a powerful predictor of heart failure events post acute myocardial infarction and in established heart failure: a literature-based meta-analysis. J Card Fail. 2007; 13 (5): 346-52.
42. Little WC, Oh J. Echocardiographic evaluation of diastolic function can be used to guide clinical care. Circulation. 2009; 120 (9): 802-9.
43. Lester SJ, Tajik A, Nishimura RA, Oh JK, Khanderia BK, Seward JB. Unlocking the misteries of diastolic function. J Am Coll Cardiol. 2008; 51 (7): 679-89.
44. Douglas P. The left atrium: a biomarker of chronic diastolic dysfunction and cardiovascular disease risk. J Am Coll Cardiol. 2003; 42 (7): 1206-7.
45. Dokainish H, Sengupta R, Pillai M, Bobek J, Lakkis N. Usefulness of new diastolic strain and strain rate indexes for the estimation of left ventricular filling pressure. Am J Cardiol. 2008; 101 (10): 1504-9.
46. Ha JW, Oh JK, Pellikka PA, Ommen SR, Stussy VL, Bailey KR, et al. Diastolic stress echocardiography: a novel noninvasive diagnostic test for diastolic dysfunction using supine bicycle exercise Doppler echocardiography. J Am Soc Echocardiogr. 2005; 18 (1): 63-8.
47. Tschöpe C, Paulus W. Is echocardiographic evaluation of diastolic function useful in determining clinical care? Doppler echocardiography yields dubious estimates of left ventricular diastolic pressures. Circulation. 2009; 120 (9): 810-20.
48. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor I. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006; 27 (19): 2338-45.
49. Massie BM, Carson P, McMurray JJ, Komajda M, McKelvie R, Zile MR. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008; 359 (23): 2456-67.
50. Yusuf S, Pfeffer M, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362 (9386): 777-81.
51. Dobre D, van Veldhuisen D, DeJongste MJ, Lucas C, Cleuren G, Sanderman R, et al. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction: clinical implications and survival. Eur J Heart Fail. 2007; 9 (3): 280-6.
52. van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M, et al. SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS. J Am Coll Cardiol. 2009; 53 (23): 2150-8.
53. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001; 345 (23): 1689-97.
54. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004; 110 (5): 558-65.
55. Little WC, Zile M, Kitzman DW, Hundley WG, ÓBrien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005; 11 (3): 191-5.
56. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov. 2007; 6 (2): 127-39.
57. Leite-Moreira AF, Castro-Chaves P, Pimentel-Nunes P, Lima-Carneiro A, Guerra MS, Soares JB, et al. Angiotensin II acutely decreases myocardial stiffness: a novel AT1, PKC and Na+/H+ exchanger-mediated effect. Br J Pharmacol. 2006; 147 (6): 690-7.
58. Leite-Moreira AF, Bras-Silva C, Pedrosa CA, Rocha-Sousa AA. ET-1 increases distensibility of acutely loaded myocardium: a novel ETA and Na+/H+ exchanger mediated effect. Am J Physiol Heart Circ Physiol. 2003; 284 (4): 1332-9.
59. Castro-Chaves P, Fontes-Carvalho R, Pintalhao M, Pimentel-Nunes P, Leite- Moreira AF. Angiotensin II-induced increase in myocardial distensibility and its modulation by the endocardial endothelium in the rabbit heart. Exp Physiol. 2009; 94 (6): 665-74.
60. Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF. Acute neurohumoral modulation of diastolic function. Peptides. 2009; 30 (2): 419-25.
61. Periasamy M, Jansen PM. Molecular basis of diastolic dysfunction. Heart. Fail Clin. 2008; 4 (1): 13-21.
62. Gupta D, Palma J, Molina E, Gaughan JP, Long W, Houser S, et al. Improved exercise capacity and reduced systemic inflammation after adenoviralmediated SERCA-2a gene transfer. J Surg Res. 2008; 145 (2): 257-65.
63. Schmidt U, del Monte F, Miyamoto MI, Matsui T, Gwathmey JK, Rosenzweig A, et al. Restoration of diastolic function in senescent rat hearts through adenoviral gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase. Circulation. 2000; 101 (7): 790-6.
64. Goldsmith SR. Type 5 Phosphodiesterase inhibition in heart failure: the next step. J Am Coll Cardiol. 2007; 50 (22): 2145-7.